HSPA5 and neoplasm: The residual tumor after neoadjuvant systemic therapy is more likely to exhibit positive CS-GRP78 expression than pre-treatment tissue, which may be due to the activation of the ERS response and the induction of GRP78 to translocate into the cell surface during chemotherapy [48].